8-K: Semler Scientific Reports Q3 Prelim Results, Bitcoin Gains

Semler Scientific announced preliminary third-quarter 2025 financial results, including significant unrealized gains from Bitcoin holdings, alongside a substantial reduction in Q4 revenue guidance due to declining QuantaFlo device usage.

Summary

• Reported preliminary unaudited revenues of $6.9 to $7.5 million for the third quarter ended September 30, 2025.
• Operating expenses for Q3 2025 are estimated at $12.8 to $13.4 million, including approximately $2.1 million in non-cash stock compensation and depreciation, and $2.1 million in non-recurring merger-related consulting and professional fees.
• Recognized an estimated unrealized gain from the change in fair value of Bitcoin holdings of approximately $30.0 million since June 30, 2025.
• Held 5,048 Bitcoins as of September 30, 2025, acquired for an aggregate of $479.0 million at an average price of $94,877 per Bitcoin, with a market value of $575.8 million.
• Cash, restricted cash, and cash equivalents were approximately $10.3 million as of September 30, 2025.
• Basic shares outstanding were 15,142,195 and assumed diluted shares outstanding were 17,296,094 as of September 30, 2025.
• Anticipates fourth quarter 2025 revenues to be at least 60% lower compared to third quarter 2025 expected revenue.
• A customer representing over 10% of revenue in Q2 and Q3 2025 has ceased use of QuantaFlo devices.
• Between August 1, 2025, and September 30, 2025, acquired 27 Bitcoins for $3.1 million at an average purchase price of $114,119 per Bitcoin.
• BTC Yield was 30.1% year-to-date through September 30, 2025.
• Issued and sold 5,207,036 shares of common stock for aggregate net proceeds of approximately $203.8 million under its At-The-Market (ATM) offering program as of September 30, 2025.

Sentiment

Score: 3

Explanation: The significant anticipated decline in core business revenue (at least 60% in Q4) and the loss of a major customer are substantial negatives. While the unrealized Bitcoin gain is a positive, it is volatile and does not offset the fundamental deterioration of the primary healthcare operations. The overall outlook for the core business is concerning.

Positives

• Reported a significant estimated unrealized gain of approximately $30.0 million from Bitcoin holdings in Q3 2025.
• Maintained substantial Bitcoin holdings of 5,048 BTC with a market value of $575.8 million as of September 30, 2025.
• Achieved a strong BTC Yield of 30.1% year-to-date through September 30, 2025, indicating effective management of its Bitcoin treasury strategy.

Negatives

• Anticipates a severe decline in fourth quarter 2025 revenues, expected to be at least 60% lower than Q3 2025 expected revenue.
• A major customer, representing over 10% of revenue in both Q2 and Q3 2025, has ceased using QuantaFlo devices.
• Operating expenses of $12.8 to $13.4 million for Q3 2025 significantly exceed preliminary revenues of $6.9 to $7.5 million, indicating operational losses.
• Further revenue declines are anticipated due to the CMS reimbursement landscape and a recent settlement with the U.S. Department of Justice.

Risks

• Volatility in Bitcoin prices could significantly impact the value of the company's Bitcoin holdings and financial results.
• Decreased usage of the QuantaFlo device due to the 2024 Medicare Advantage and Part D Final Rate Announcement by CMS poses a significant threat to core business revenue.
• Customer attrition, including a major customer ceasing QuantaFlo use, directly impacts revenue and future growth prospects.
• Risks associated with the proposed merger with Strive Inc., including potential termination, failure to close, difficulties in integration, and unrealized strategic or financial benefits.
• Potential dilution for existing shareholders due to the At-The-Market (ATM) offering program and Strive's issuance of additional shares in connection with the proposed transaction.
• The preliminary unaudited financial information is subject to change and may differ from final results.

Future Outlook

Fourth quarter 2025 revenues are anticipated to be at least 60% lower compared to the third quarter 2025 expected revenue. Further revenue declines are expected as other customers cease use of QuantaFlo due to the CMS reimbursement landscape and the recent DOJ settlement. The company is also progressing with a proposed merger transaction with Strive Inc.

Management Comments

• Management believes the BTC Yield KPI can be used to supplement an investor's understanding of the decision to fund Bitcoin purchases by issuing additional shares of common stock or convertible instruments.

Industry Context

The significant anticipated decline in QuantaFlo device usage and associated revenue is a direct consequence of changes in the 2024 Medicare Advantage and Part D Final Rate Announcement by the Centers for Medicare and Medicaid Services (CMS). This highlights the profound impact of regulatory and reimbursement policy shifts on the medical device and healthcare services industry. Semler Scientific's strategy of holding substantial Bitcoin assets, while generating significant unrealized gains, positions it uniquely outside traditional healthcare industry norms, introducing a new dimension of digital asset exposure and volatility to its business model.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders face potential dilution from the ongoing ATM offering and the proposed merger with Strive Inc.
• Shareholders are exposed to significant volatility due to the company's substantial Bitcoin holdings.
• Customers of QuantaFlo devices are ceasing usage, impacting the company's revenue and potentially their access to the device.
• Employees may face uncertainty regarding job security and strategic direction given the declining core business and proposed merger.

Next Steps

• Finalize full financial results for the third quarter ended September 30, 2025.
• Strive Inc. intends to file a Registration Statement on Form S-4, which will include an Information Statement/Proxy Statement/Prospectus, in connection with the proposed merger.
• Semler Scientific stockholders will be sent a definitive Information Statement/Proxy Statement/Prospectus to seek their approval of the proposed transaction.

Key Dates

Recommendation

The core business of Semler Scientific is facing severe headwinds, evidenced by the anticipated Q4 2025 revenue decline of at least 60% and the loss of a significant customer. This fundamental deterioration overshadows the substantial, but volatile and unrealized, gains from Bitcoin holdings. While the Bitcoin strategy has provided a financial boost, it introduces significant risk and deviates from the company's original healthcare focus. The company's operating expenses are significantly higher than its preliminary revenues, indicating an unsustainable operational model without the Bitcoin gains. Given the severe challenges to the primary business, the stock carries substantial risk, making a 'sell' recommendation appropriate for investors seeking stability and predictable growth.

Keywords

Semler Scientific, Bitcoin, SMLR, Q3 2025, Preliminary Financials, Revenue Guidance, QuantaFlo, CMS, ATM Offering, Strive Inc., Merger, Digital Assets, Healthcare Technology